Skip to main content

CIPLA PREGABALIN, CIPGABLIN, PREGACIPLIN (Cipla Australia Pty Ltd)

Product name
CIPLA PREGABALIN, CIPGABLIN, PREGACIPLIN
Date registered
Evaluation commenced
Decision date
Approval time
157 working days (255)
Active ingredients
pregabalin
Registration type
New generic medicine
Indication

CIPLA PREGABALIN, CIPGABLIN, PREGACIPLIN (capsules) are indicated for the treatment of neuropathic pain in adults.

CIPLA PREGABALIN, CIPGABLIN, PREGACIPLIN are indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Help us improve the Therapeutic Goods Administration site